TGFB1 and neoplasm: These results establish that disrupting IL-6 signaling in Pan02 tumors during active immune modulation by the TGFβ vaccine impairs the development of CD4+ TGFβ-specific T cells, hampers tumor T-cell infiltration, and contributes to CD4+ T-cell exhaustion.